Glaxo tops quarterly expectations, consumer arm spin off on track
British drugmaker GSK on Wednesday beat analyst expectations for its first-quarter profit and sales, ahead of the planned listing of its large consumer healthcare division in July, and stood by its forecasts for 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.